ORAL, F. Et Al. 2019. Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. RHEUMATOLOGY , vol.58, no.5 , 925.

ORAL, F., BİLGİN, E., BÖLEK, E. Ç., YARDIMCI, G. K., & KILIÇ, L., (2019). Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. RHEUMATOLOGY , vol.58, no.5, 925.

ORAL, FATMA Et Al. "Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial," RHEUMATOLOGY , vol.58, no.5, 925, 2019

ORAL, FATMA Et Al. "Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial." RHEUMATOLOGY , vol.58, no.5, pp.925, 2019

ORAL, F. Et Al. (2019) . "Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial." RHEUMATOLOGY , vol.58, no.5, p.925.

@article{article, author={FATMA YALÇINKAYA Et Al. }, title={Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial}, journal={RHEUMATOLOGY}, year=2019, pages={925} }